ClinicalTrials.gg
CompletedNCT04108208Updated Jul 30, 2026Results posted

A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Prostate Cancer (NM-CRPC)

A Phase 4 interventional study of Apalutamide and Placebo in Prostatic Neoplasms, sponsored by Janssen Research & Development, LLC. Completed at 27 sites in China. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-30.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 70 studies testing apalutamide in Prostatic Neoplasms — 14 open to participants now, 36 under way, 12 of them phase 3. apalutamide · Prostatic Neoplasms.

Enrollment
36th of 70
75 · median 81
Started
2019
with 5 others
Phase 4
2 of 70
1 open now
Registered
43rd of 70
by date
Lead sponsor
5 of 70
Janssen Research & Development, LLC

Among the 70 studies testing apalutamide in Prostatic Neoplasms, this one is the 36th largest by enrollment, is one of 6 that started in 2019, is one of 2 in phase 4, and was the 43rd registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

14 of the 70 studies testing apalutamide in Prostatic Neoplasms are open now, in 11 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About apalutamide

apalutamide: first FDA approval 2018 (ERLEADA), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies testing apalutamide in Prostatic Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to compare the improvement in time to prostate specific antigen (PSA) progression (TTPP, as defined by Prostate Cancer Working Group 2 [PCWG2]) of apalutamide versus placebo in Chinese participants with high-risk non-metastatic castration resistant prostate cancer (NM-CRPC).

03

Conditions studied

  • Prostatic Neoplasms

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features, with high risk for development of , defined as prostate-specific antigen doubling time (PSADT) less than or equals to (\<=) 10 months. PSADT is calculated using at least 3 prostate-specific antigen (PSA) values obtained during continuous androgen deprivation therapy (ADT)
  • Castration-resistant prostate cancer (PC) demonstrated during continuous ADT, defined as 3 PSA rises at least 1 week apart, with the last PSA greater than (>) 2 nanogram per milliliter (ng/mL)
  • Surgically or medically castrated, with testosterone levels of less than (\<) 50 nanogram per deciliter (ng/dL). If the participant is medically castrated, continuous dosing with gonadotropin releasing hormone analog (GnRHa) must have been initiated at least 4 weeks prior to randomization and must be continued throughout the study to maintain castrate levels of testosterone
  • Participants who received a first-generation anti-androgen (example: bicalutamide, flutamide, nilutamide) must have at least a 4-week prior to randomization and must show continuing disease progression (an increase in PSA) after washout
  • At least 4 weeks must have elapsed from major surgery or radiation therapy prior to randomization

Exclusion criteria

Exclusion Criteria:

  • Presence of distant , including central nervous system (CNS) and vertebral or meningeal involvement, or history of distant metastases. Exception: Pelvic lymph nodes \<2 centimeter in short axis (N1) located below the iliac bifurcation are allowed
  • Symptomatic loco-regional disease requiring medical intervention, such as moderate or severe urinary obstruction or hydronephrosis, due to primary tumor (example, tumor obstruction of bladder trigone)
  • Prior treatment with cytochrome P450 17 alpha-hydroxylase/17,20-lyase (CYP17) inhibitors (example: abiraterone acetate, orteronel, galerterone, ketoconazole, aminoglutethimide) for PC
  • Prior chemotherapy for PC, except if administered in the /neoadjuvant setting
  • Prior treatment with second generation anti-androgens (example, enzalutamide)
  • History of seizure or condition that may pre-dispose to seizure (example: prior stroke within 1 year prior to randomization, brain arteriovenous malformation, schwannoma, meningioma, or other benign CNS or meningeal disease which may require treatment with surgery or radiation therapy)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
75 participants (actual)

Study arms

  • Experimental
    Apalutamide 240 milligram (mg) plus ADT

    Participants will receive apalutamide 240 mg orally daily from Day 1 of Cycle 1 until disease progression, unacceptable toxicity, withdrawal of consent, death or termination of the study along with androgen-deprivation therapy (ADT). Each treatment cycle will consist of 28 days.

    Drug: Apalutamide · Drug: Androgen-deprivation Therapy (ADT)

  • Placebo comparator
    Placebo plus ADT

    Participants will receive matching placebo daily along with ADT from Cycle 1 Day 1 until disease progression, unacceptable toxicity, withdrawal of consent, death or termination of the study. Participants who do not have distant metastasis will switch to treatment with apalutamide after completion of 5 cycles of placebo treatment. Participants who have prostate-specific antigen (PSA) progression prior to completion of 5 cycles of study treatment, will cross over to apalutamide at the time of PSA progression. Each treatment cycle will consist of 28 days.

    Drug: Placebo · Drug: Androgen-deprivation Therapy (ADT)

Interventions

  • Apalutamide 240 mg (4\*60 mg tablets) will be administrated orally once daily.

    Also known as: JNJ-56021927, ARN-509

  • DrugPlacebo

    Matching placebo will be administered orally.

  • DrugAndrogen-deprivation Therapy (ADT)

    Participants will continue to receive ADT with gonadotrophin-releasing hormone agonists (GnRHa) who have not been surgically castrated.

06

What researchers measure

Primary outcomes

  1. Time to Prostate Specific Antigen (PSA) Progression (TTPP) Based on Prostate Cancer Working Group 2 (PCWG2) Criteria

    Time to prostate specific antigen progression (TTPP) was defined as the time from randomization to the first date of documented PSA progression based on PCWG2 criteria. PCWG2 was defined as the PSA progression as 1) the date that a 25 percent (%) or greater increase and an absolute increase of 2 nanograms per milliliter (ng/mL) or more from the Nadir was documented, which was confirmed by a second value obtained 3 or more weeks later. 2) Where no decline from baseline was documented as a 25% increase from the baseline value along with an increase in absolute value of 2 ng/mL or more after 12 week of treatment. Kaplan-Meier method was used for the analysis.

    Time frame: From randomization until first documented PSA progression (up to 3 years 3 months)

Secondary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)

    Time frame: Up to 6 years 4 months

  2. Number of Participants With Grade 3 or Higher Abnormalities in Laboratory Values

    Time frame: Up to 6 years 4 months

  3. Percentage of Participants Who Achieved Prostate Specific Antigen (PSA) Response (>=50% PSA Reduction)

    Time frame: Up to 6 years 4 months

  4. Plasma Concentration of Apalutamide and Its Metabolite (N-desmethyl Apalutamide)

    Time frame: Presdose: Day 1 of Cycles 1, 2, 3, and 6; 2 hours postdose: Day 1 of Cycles 1 and 3

07

Results

Posted Mar 28, 2025

Participant flow

Participant flow — Overall Study
MilestonePlacebo Plus Androgen-deprivation Therapy (ADT)Apalutamide 240 mg Plus ADT
Started2550
Crossed-over to apalutamide220
Completed00
Not completed2550
Withdrew: Withdrawal by subject26
Withdrew: Other-ongoing2040
Withdrew: Death14
Withdrew: Lost to follow-up20

Outcome measures

PrimaryTime to Prostate Specific Antigen (PSA) Progression (TTPP) Based on Prostate Cancer Working Group 2 (PCWG2) Criteria

Time to prostate specific antigen progression (TTPP) was defined as the time from randomization to the first date of documented PSA progression based on PCWG2 criteria. PCWG2 was defined as the PSA progression as 1) the date that a 25 percent (%) or greater increase and an absolute increase of 2 nanograms per milliliter (ng/mL) or more from the Nadir was documented, which was confirmed by a second value obtained 3 or more weeks later. 2) Where no decline from baseline was documented as a 25% increase from the baseline value along with an increase in absolute value of 2 ng/mL or more after 12 week of treatment. Kaplan-Meier method was used for the analysis.

Time frame:
From randomization until first documented PSA progression (up to 3 years 3 months)
Reported as:
Median · Months
Time to Prostate Specific Antigen (PSA) Progression (TTPP) Based on Prostate Cancer Working Group 2 (PCWG2) Criteria
MonthsPlacebo Plus Androgen-deprivation Therapy (ADT)Apalutamide 240 mg Plus ADT
Time to Prostate Specific Antigen (PSA) Progression (TTPP) Based on Prostate Cancer Working Group 2 (PCWG2) CriteriaNA (3.55 to NA)NA (25.76 to NA)
Statistical analysis
  • Placebo Plus Androgen-deprivation Therapy (ADT) vs Apalutamide 240 mg Plus ADT · Log Rank · p = =0.0052 · Hazard ratio (hr): 0.233 · 95% CI 0.077 to 0.705
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)
Time frame:
Up to 6 years 4 months

Results for this outcome have not been posted.

SecondaryNumber of Participants With Grade 3 or Higher Abnormalities in Laboratory Values
Time frame:
Up to 6 years 4 months

Results for this outcome have not been posted.

SecondaryPercentage of Participants Who Achieved Prostate Specific Antigen (PSA) Response (>=50% PSA Reduction)
Time frame:
Up to 6 years 4 months

Results for this outcome have not been posted.

SecondaryPlasma Concentration of Apalutamide and Its Metabolite (N-desmethyl Apalutamide)
Time frame:
Presdose: Day 1 of Cycles 1, 2, 3, and 6; 2 hours postdose: Day 1 of Cycles 1 and 3

Results for this outcome have not been posted.

Adverse events

Collected over Serious adverse events (AEs) and other AEs: From Cycle 1 Day 1 up to 30 days post last dose of study drug (up to 38.3 months); all-cause mortality: from Cycle 1 Day 1 up to 3 years and 3 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo Plus Androgen-deprivation Therapy (ADT)1/25 (4%)4/25 (16%)11/25 (44%)
Apalutamide 240 mg Plus ADT4/50 (8%)20/50 (40%)47/50 (94%)
Placebo + ADT to Apalutamide + ADT0/22 (0%)5/22 (22.7%)21/22 (95.5%)
All Participants: Apalutamide 240 mg Plus ADT4/72 (5.6%)25/72 (34.7%)68/72 (94.4%)
Most frequent serious events
Showing 10 of 28
Most frequent serious events
EventPlacebo Plus Androgen-deprivation Therapy (ADT)Apalutamide 240 mg Plus ADTPlacebo + ADT to Apalutamide + ADTAll Participants: Apalutamide 240 mg Plus ADT
PneumoniaInfections and infestations0/255/500/225/72
LeukopeniaBlood and lymphatic system disorders0/250/501/221/72
Gastritis ErosiveGastrointestinal disorders0/250/501/221/72
Covid-19Infections and infestations0/252/501/223/72
SepsisInfections and infestations0/250/501/221/72
Femur FractureInjury, poisoning and procedural complications0/250/501/221/72
Dermatitis Exfoliative GeneralisedSkin and subcutaneous tissue disorders0/250/501/221/72
Mixed DeafnessEar and labyrinth disorders1/250/500/220/72
Gastrointestinal Stromal TumourNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/250/500/220/72
Cerebral InfarctionNervous system disorders1/250/500/220/72
Most frequent other events
Showing 10 of 36
Most frequent other events
EventPlacebo Plus Androgen-deprivation Therapy (ADT)Apalutamide 240 mg Plus ADTPlacebo + ADT to Apalutamide + ADTAll Participants: Apalutamide 240 mg Plus ADT
AnaemiaBlood and lymphatic system disorders3/2515/505/2220/72
RashSkin and subcutaneous tissue disorders3/2514/504/2218/72
Covid-19Infections and infestations0/256/505/2211/72
HypertensionVascular disorders2/2511/503/2214/72
Weight DecreasedInvestigations0/2510/502/2212/72
HyperglycaemiaMetabolism and nutrition disorders0/2510/503/2213/72
PyrexiaGeneral disorders1/250/504/224/72
LeukopeniaBlood and lymphatic system disorders0/259/503/2212/72
Rib FractureInjury, poisoning and procedural complications1/255/502/227/72
HyperkalaemiaMetabolism and nutrition disorders0/255/500/225/72

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Placebo Plus Androgen-deprivation Therapy (ADT)Apalutamide 240 mg Plus ADTTotal
Mean74.5 ± 7.8275.1 ± 7.9074.9 ± 7.83
Sex: Female, Male
Sex: Female, Male(Participants)Placebo Plus Androgen-deprivation Therapy (ADT)Apalutamide 240 mg Plus ADTTotal
Female000
Male255075
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo Plus Androgen-deprivation Therapy (ADT)Apalutamide 240 mg Plus ADTTotal
American Indian or Alaska Native000
Asian255075
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)Placebo Plus Androgen-deprivation Therapy (ADT)Apalutamide 240 mg Plus ADTTotal
China255075
08

Study locations

27 sites
  • Cancer Hospital Chinese Academy of Medical Sciences
    Beijing, 100021, China
  • Peking University First Hospital
    Beijing, 100034, China
  • Peking University People's Hospital
    Beijing, 100044, China
  • Beijing Friendship Hospital
    Beijing, 100050, China
  • Peking University Third Hospital
    Beijing, 100191, China
  • Beijing Hospital
    Beijing, 100730, China
  • Hunan Cancer hospital
    Changsha, 410013, China
  • Sichuan Provincial Peoples Hospital
    Chengdu, 610072, China
  • Chongqing University Cancer Hospital
    Chongqing, 400030, China
  • Fujian Medical University Union Hospital
    Fuzhou, 350001, China
  • Sun Yat-Sen Memorial Hospital Sun Yat-sen University
    Guangzhou, 510120, China
  • Guangzhou First Municipal People's Hospital
    Guangzhou, 510180, China
  • Zhejiang Provincial People's Hospital
    Hangzhou, 310000, China
  • The First Affiliated Hospital Zhejiang University College of Medicine
    Hangzhou, 310003, China
  • Zhejiang Cancer Hospital
    Hangzhou, 310022, China
  • Nanjing Drum Tower Hospital
    Nanjing, 210008, China
  • The First Affiliated Hospital of Ningbo University
    Ningbo, 315010, China
  • Cancer Hospital, FuDan University
    Shanghai, 200032, China
  • Shanghai Zhongshan Hospital
    Shanghai, 200032, China
  • Huashan Hospital Fudan University
    Shanghai, 200040, China
  • Renji Hospital, Shanghai Jiaotong University School of Medicine
    Shanghai, 200240, China
  • The Fifth People's Hospital of Shanghai, Fudan University
    Shanghai, 200240, China
  • Huadong Hospital Affiliated to Fudan University
    Shanghai, 200400, China
  • First Affiliated Hospital SooChow University
    Suzhou, 215006, China
  • TongJi Hospital of TongJi Medical College of Huazhong University of Science & Technology
    Wuhan, 430030, China
  • Wuxi People s Hospital
    Wuxi, 214023, China
  • The First Affiliated Hospital of Xian Jiaotong University
    Xi'an, 710061, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · www.janssen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2019 to primary completion in Jun 2023, 41 months.

Results were first posted in Mar 2025, 1 year 9 months after primary completion.

Of 52 phase 4 interventional studies under Prostatic Neoplasms, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 67. This study's 41 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2019
First posted
Sep 30, 2019
StartActual
Dec 17, 2019
Primary completionActual
Jun 1, 2023
CompletionActual
Jun 5, 2026
Results first posted
Mar 28, 2025
Last update
Jul 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04108208
Responsible party
Sponsor
First posted
Sep 30, 2019
Start date
Dec 17, 2019
Primary completion
Jun 1, 2023
Completion
Jun 5, 2026
Results posted
Mar 28, 2025
Last update
Jul 30, 2026

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apalutamide

Start the discussion